Search results for "Blood coagulation"

showing 10 items of 154 documents

Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids

2021

ChemistryMyocardiumImmunologySkeletal muscleCell BiologyHematologyMyosinsLetter to BLOODBiochemistryCell biologyCardiac Myosinsmedicine.anatomical_structureMyosinmedicineAnimalsHumansRabbitsMuscle SkeletalBlood CoagulationCardiac MyosinsPhospholipidsBlood
researchProduct

ProC Global: the first functional screening assay for the complete protein C pathway.

1997

Abstract In clinical practice, venous thromboembolic complications are much more frequent than bleeding disorders. In fact, disturbances within the protein C pathway due to coagulation factor V (FV) Leiden mutation and deficiency of protein C or protein S are the most frequent abnormalities in hereditary thrombophilia. Furthermore, acquired dysfunctions of the protein C system may predispose the single individual to an increased thrombotic risk. A routine-suited screening assay that would allow the monitoring of the proper interplay of factors in the protein C pathway could add an important factor to the basic coagulation profile. This consists of the prothrombin time and of the activated p…

Clinical BiochemistryBlood DonorsSensitivity and SpecificityProtein SProtein SProtein C deficiencyReference ValuesMedicineHumansMass ScreeningProtein S deficiencyProthrombin timemedicine.diagnostic_testbiologybusiness.industryBiochemistry (medical)Factor VFactor VProtein C DeficiencyReproducibility of ResultsThrombosisBlood Coagulation Disordersmedicine.diseaseImmunologyMutationbiology.proteinCancer researchPartial Thromboplastin TimeDisease SusceptibilityReagent Kits DiagnosticActivated protein C resistancebusinessProtein CPartial thromboplastin timemedicine.drugProtein CClinical chemistry
researchProduct

Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.

2018

Introduction: Cushing’s disease (CD) is characterized by procoagulative profile. Treatment with cortisol-reducing medications might normalize the coagulation impairment potentially eliminating the risk of thromboembolic complications. Aim: The aim of this prospective study is to evaluate the effectiveness of 6–12 months of treatment with pasireotide (Signifor®, Novartis) 600 µg twice daily on coagulative factors in 21 patients (16 females, mean age 46 ± 12.2 years) with CD. Biochemical, hormonal (urinary free cortisol, UFC; late night salivary cortisol, LNSC; ACTH) and coagulative parameters as Protrombin time (PT), aPTT, factors VIII, IX and XI, antithrombin III, protein C, protein S, fibr…

Cortisol secretionAdultBlood GlucoseMalemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterologySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumansProspective StudiesProspective cohort studyThromboprophylaxisPituitary ACTH HypersecretionBlood CoagulationClotting factorCoagulationbusiness.industryAnticoagulantCoagulation; Cushing’s disease; Pasireotide; Pituitary; Thromboprophylaxis; Endocrinology Diabetes and Metabolism; EndocrinologyCushing's diseaseCushing’s diseaseMiddle Agedmedicine.diseasePasireotidePasireotideDiabetes and MetabolismCoagulative necrosisTreatment OutcomechemistryPituitary030220 oncology & carcinogenesisConcomitantThromboprophylaxiFemaleBlood Coagulation TestsbusinessSomatostatinEndocrine
researchProduct

Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches

2020

Great efforts are being made worldwide to identify the specific clinical characteristics of infected critically ill patients that mediate the associated pathogenesis, including vascular dysfunction, thrombosis, dysregulated inflammation, and respiratory complications. Recently, coronavirus disease 2019 has been closely related to sepsis, which suggests that most deaths in ICUs in infected patients are produced by viral sepsis. Understanding the physiopathology of the disease that lead to sepsis after severe acute respiratory syndrome coronavirus 2 infection is a current clinical need to improve intensive care-applied therapies applied to critically ill patients. Although the whole represent…

Critical CareAnti-Inflammatory AgentsInflammationDiseaseCritical Care and Intensive Care MedicinesepsisSepsisPathogenesis03 medical and health sciences0302 clinical medicineImmune systemCoagulopathymedicineHumansanti-inflammatory therapyGlucocorticoidsRespiratory Distress SyndromeSARS-CoV-2business.industryCOVID-19Thrombosis030208 emergency & critical care medicineBlood Coagulation Disordersmedicine.diseaseThrombosisPathophysiologyViewpoints030228 respiratory systemcytokine stormImmunologyCytokinesmedicine.symptombusinesssevere acute respiratory syndrome coronavirus 2Critical Care Medicine
researchProduct

Thromboinflammation and Vascular Dysfunction.

2018

Thromboinflammation and vascular dysfunction are inseparably combined with the innate and the adaptive immune response. While the role of this interplay has gained considerable attention in the arena of atherosclerosis/atherothrombosis and in deep vein thrombosis, its role in other forms of vascular disease and risk factors is currently emerging. In this brief review, we will focus on thromboinflammation with regard to cytokine signalling as well as on the novel role of a vascular coagulation-inflammatory circuit in arterial hypertension.Thrombo-Inflammation und vaskuläre Dysfunktion sind untrennbar mit dem angeborenen und dem erworbenen Immunsystem verbunden. Dieses Zusammenspiel wurde im …

Deep veinInflammation030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineImmune systemCoagulation cascademedicineAnimalsHumansCytokine signallingBlood CoagulationInflammationbusiness.industryVascular diseaseThrombosisHematologymedicine.diseaseAcquired immune systemThrombosismedicine.anatomical_structureBlood Vesselsmedicine.symptombusiness030215 immunologyHamostaseologie
researchProduct

Oxcarbazepine does not affect the anticoagulant activity of warfarin.

1992

The possible interaction of the antiepileptic drug oxcarbazepine (OCBZ) on the anticoagulant effect of warfarin was investigated in 10 healthy male volunteers. After reaching steady-state conditions by repeated administration of warfarin, the prothrombin time (Quick value) was assessed before and after single (600 mg) and multiple dosing (450 mg twice daily in 1 week) of OCBZ. In 7 of the 10 volunteers with evaluable data, the prothrombin time was not significantly different (paired t test) from baseline either after single (p = 0.299) or repeated dosing (p = 0.333), indicating that OCBZ does not interact to any relevant extent with the hypothrombinemic effect of warfarin.

DrugAdultMalemedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentOxcarbazepinePharmacologymedicineHumansDrug InteractionsOxcarbazepineBlood Coagulationmedia_commonProthrombin timeChemotherapymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryAnticoagulantWarfarinDose–response relationshipAnticonvulsantCarbamazepineNeurologyAnesthesiaProthrombin TimeAnticonvulsantsNeurology (clinical)Warfarinbusinessmedicine.drugEpilepsia
researchProduct

Role of the protein C receptor in cancer progression

2014

The hemostatic system plays pleiotropic roles in cancer progression by shaping the tumor microenvironment and metastatic niches through thrombin-dependent fibrin deposition and platelet activation. Expanding experimental evidence implicates coagulation protease receptors expressed by tumor cells as additional players that directly influence tumor biology. Pro-angiogenic G protein-coupled signaling of TF through protease activated receptor 2 and regulation of tumor cell and vascular integrins through ligation by alternative spliced TF are established pathways driving tumor progression. Our recent work shows that the endothelial protein C receptor (EPCR), a stem cell marker in hematopoietic, …

Endothelial protein C receptorTumor microenvironmentCD30Endothelial Protein C ReceptorBreast NeoplasmsReceptors Cell SurfaceHematologyBiologyStem cell markerArticleAntigens CDTumor progressionCancer stem cellDisease ProgressionTumor MicroenvironmentCancer researchAnimalsHumansFemalePlatelet activationBlood CoagulationProtease-activated receptor 2Signal TransductionThrombosis Research
researchProduct

Graphene coating obtained in a cold-wall CVD process on the Co-Cr Alloy (L-605) for medical applications

2021

Graphene coating on the cobalt-chromium alloy was optimized and successfully carried out by a cold-wall chemical vapor deposition (CW-CVD) method. A uniform layer of graphene for a large area of the Co-Cr alloy (discs of 10 mm diameter) was confirmed by Raman mapping coated area and analyzing specific G and 2D bands

ErythrocytesMicroscopeScanning electron microscope02 engineering and technologyChemical vapor deposition01 natural scienceslaw.inventionlcsh:ChemistryMiceCoated Materials BiocompatibleCoatinglawMaterials TestingComposite materiallcsh:QH301-705.5SpectroscopySettore CHIM/02 - Chimica Fisicagraphene coating ; biocompatibility ; cobalt chromium alloy ; cold wall chemical vapor deposition methodGeneral Medicine021001 nanoscience & nanotechnologyMicrostructureBlood Coagulation FactorsComputer Science ApplicationsGraphitePartial Thromboplastin TimeBiocompatibility0210 nano-technologyLayer (electronics)Blood PlateletsMaterials scienceCell SurvivalSurface PropertiesPrimary Cell Cultureengineering.material010402 general chemistryCobalt-chromium alloyGraphene coatingCold-wall chemical vapor deposition methodArticleCatalysisInorganic ChemistryAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyGrapheneOrganic Chemistrytechnology industry and agricultureNanoindentationPlatelet Activation0104 chemical scienceslcsh:Biology (General)lcsh:QD1-999NIH 3T3 CellsengineeringChromium AlloysVolatilization
researchProduct

Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia?

2020

Introduction Certain haemophilia carriers demonstrate an increased bleeding tendency, mainly related to clotting factor deficiency. No study has so far formally compared the bleeding phenotype of women and girls with mild FVIII or FIX deficiency and associated management with that of male patients affected by mild haemophilia A and B. Material and methods We retrospectively evaluated 44 women and girls with mild FVIII or FIX deficiency (FVIII or FIX 0.05-0.5 IU/mL) and 77 male patients with mild haemophilia A or B and compared them with respect to clotting factor level, age at and trigger for diagnosis, as well as treatment modalities. Results After excluding gender-related haemorrhagic sym…

FVIIImild haemophiliaAdultMalePediatricsmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesHeterozygoteAdolescentMucocutaneous zonecarriersPlasma factorAge at diagnosis030204 cardiovascular system & hematologyHaemophiliaHemophilia AHemostatics03 medical and health sciencesYoung Adult0302 clinical medicinecarrierhemic and lymphatic diseasesmedicineHumansDeamino Arginine VasopressinClotting factor deficiencyChildGenetics (clinical)AgedClotting factorAged 80 and overbusiness.industryFIXHematologyGeneral MedicineMiddle Agedmedicine.diseaseBlood Coagulation Factorsbleeding phenotypebleeding phenotype carriers FIX FVIII mild haemophiliaMale patientChild PreschoolMild haemophilia AFemalebusiness030215 immunologyHaemophilia : the official journal of the World Federation of HemophiliaREFERENCES
researchProduct

Pain assessment and management in Italian Haemophilia Centres

2021

BACKGROUND: Although the widespread use of factor VIII/IX replacement therapy has significantly reduced the severity of arthropathy in persons with haemophilia (PWH), some develop degenerative joint changes, associated with significant pain. The aim of this survey was to investigate the management and perception of pain among Italian physicians who treat PWH. MATERIALS AND METHODS: Between September and October 2017, a questionnaire was distributed to 35 Italian haemophilia treatment centres (60 physicians). RESULTS: Fifty-three haemophilia specialists completed the survey. We found that there was good agreement (98.1%) on the need to investigate pain at each clinical visit, but there was h…

Factor IXItalyHumansPain Managementpain heamophiliaHemophilia Ablood coagulation disorders haemophilia pain perception pain management surveysHaemostasis and ThrombosisPain Measurement
researchProduct